-+ 0.00%
-+ 0.00%
-+ 0.00%

Creative Medical Technology Holdings Says WHO Assigns "Olastrocel" As International Non-Proprietary Name For Lead Cell Therapy CELZ-201

Benzinga·12/02/2025 14:19:41
Listen to the news

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company developing next-generation regenerative and immune cell therapies, today announced that the World Health Organization (WHO) has approved "olastrocel" as the International Non-Proprietary Name (INN) for the active cellular substance in CELZ-201, the Company's lead allogeneic cell therapy also known as AlloStem®.

The INN is the globally standardized, unique scientific name used by regulators, clinicians, researchers, and global markets to identify a therapeutic substance throughout its development and commercialization lifecycle. This assignment is a key global milestone that typically occurs as a program advances into later regulatory stages and requires unified international identification.